Journal
NPJ BREAST CANCER
Volume 8, Issue 1, Pages -Publisher
NATURE PORTFOLIO
DOI: 10.1038/s41523-022-00469-z
Keywords
-
Categories
Funding
- National Institutes of Health (NIH)/National Cancer Institute (NCI) Cancer Center Support Grant [P30 CA008748]
- NIH/NCI [P50 CA247749 01]
- Breast Cancer Research Foundation
Ask authors/readers for more resources
Breast adenoid cystic carcinoma is a rare subtype of triple negative breast cancer with two morphologic variants. Recent studies have shown that one variant has a worse prognosis and there are currently no standard recommendations for its management. Data on chemotherapy and response to neoadjuvant chemotherapy are limited.
Breast adenoid cystic carcinoma (AdCC) is a rare subtype of triple negative breast cancer. Two morphologic variants are described, namely classic AdCC (C-AdCC) and solid basaloid (SB-AdCC). Recent studies have shown that the SB-AdCC variant has significantly worse prognosis than C-AdCC. Due to the rarity of SB-AdCC, no standard recommendations are available for its management. Data on the use and benefit of chemotherapy in patients with SB-AdCC are sparse and the response to neoadjuvant chemotherapy has not been reported. We present the clinical and pathologic findings of a patient with SB-AdCC treated with neoadjuvant chemotherapy who achieved a remarkable pathologic response.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available